Indolent non-Hodgkin lymphomas (iNHL) are a heterogeneous group of pathologies characterized by a prolonged natural history and good response to treatment. They also have a tendency to relapse, in some cases with a worse prognosis. One of the main objectives in the newest clinical trials is to identify patients at high risk of relapse. This cannot be accomplished using only clinical prognostic scores. Detection of minimal residual disease (MRD) is effective in evaluating long-term disease response, with a strong and independent predictive value that was demonstrated in large cohorts of patients. Analysis of MRD allows patient stratification based on the risk for relapse; therefore, different therapeutic programs can be designed based on the response characteristics. This tailored therapy is already happening in current clinical trials. Limits imposed by traditional PCR-based tools are being overcome due to new molecular biology techniques like droplet digital PCR and next generation sequencing. Although these techniques are not yet standardized, they will likely increase the reliability and ensure broad applicability of MRD detection in future years.

Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment

Grimaldi D.;Genuardi E.;Ferrante M.;Ferrero S.;Ladetto M.
Last
2018

Abstract

Indolent non-Hodgkin lymphomas (iNHL) are a heterogeneous group of pathologies characterized by a prolonged natural history and good response to treatment. They also have a tendency to relapse, in some cases with a worse prognosis. One of the main objectives in the newest clinical trials is to identify patients at high risk of relapse. This cannot be accomplished using only clinical prognostic scores. Detection of minimal residual disease (MRD) is effective in evaluating long-term disease response, with a strong and independent predictive value that was demonstrated in large cohorts of patients. Analysis of MRD allows patient stratification based on the risk for relapse; therefore, different therapeutic programs can be designed based on the response characteristics. This tailored therapy is already happening in current clinical trials. Limits imposed by traditional PCR-based tools are being overcome due to new molecular biology techniques like droplet digital PCR and next generation sequencing. Although these techniques are not yet standardized, they will likely increase the reliability and ensure broad applicability of MRD detection in future years.
19
12
71
80
http://www.springerlink.com/content/1527-2729
ddPCR; FL; MRD; NGS; Predictive value; Antineoplastic Agents, Immunological; High-Throughput Nucleotide Sequencing; Humans; Immunoglobulin Heavy Chains; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Rituximab
Grimaldi D.; Genuardi E.; Ferrante M.; Ferrero S.; Ladetto M.
File in questo prodotto:
File Dimensione Formato  
Grimaldi CTOO 2018.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 387.29 kB
Formato Adobe PDF
387.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1728893
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact